Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19055
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBowyer, Samantha-
dc.contributor.authorPrithviraj, Prashanth-
dc.contributor.authorLorigan, Paul-
dc.contributor.authorLarkin, James-
dc.contributor.authorMcArthur, Grant-
dc.contributor.authorAtkinson, Victoria-
dc.contributor.authorMillward, Michael-
dc.contributor.authorKhou, Muoi-
dc.contributor.authorDiem, Stefan-
dc.contributor.authorRamanujam, Sangeetha-
dc.contributor.authorKong, Ben-
dc.contributor.authorLiniker, Elizabeth-
dc.contributor.authorGuminski, Alexander-
dc.contributor.authorParente, Phillip-
dc.contributor.authorAndrews, Miles C-
dc.contributor.authorParakh, Sagun-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorLong, Georgina V-
dc.contributor.authorCarlino, Matteo S-
dc.contributor.authorKlein, Oliver-
dc.date2017-03-21-
dc.date.accessioned2018-09-13T00:14:46Z-
dc.date.available2018-09-13T00:14:46Z-
dc.date.issued2017-04-11-
dc.identifier.citationBritish Journal of Cancer 2017; 116(8): e15-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19055-
dc.language.isoeng-
dc.titleReply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.-
dc.typeJournal Article-
dc.identifier.journaltitleBritish Journal of Cancer-
dc.identifier.affiliationThe Christie NHS Foundation Trust and University of Manchester, Manchester, UKen
dc.identifier.affiliationRoyal Marsden Hospital NHS Foundation Trust, London, UKen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationUniversity of Sydney, Sydney, New South Wales, Australiaen
dc.identifier.affiliationBox Hill Hospital, Melbourne, Victoria, Australiaen
dc.identifier.affiliationPrincess Alexandra Hospital, Greenslopes Private Hospital, Brisbane, Queensland, Australiaen
dc.identifier.affiliationPeter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australiaen
dc.identifier.affiliationMelanoma Institute Australia, Sydney, New South Wales, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Medicine and Pharmacology, University of Western Australia, Australia, Nedlands, Western Australia, Australiaen
dc.identifier.affiliationRockingham General Hospital, Perth, Western Australia, Australiaen
dc.identifier.affiliationWestmead Hospital, Sydney, New South Wales, Australiaen
dc.identifier.doi10.1038/bjc.2017.59-
dc.identifier.pubmedid28324885-
dc.type.austinJournal Article-
local.name.researcherCebon, Jonathan S
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Jun 14, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.